Physician profile
Danielle Mathis
NPI 1982088597
$2,212.62
in general payments reported to CMS, 2019-2025
18 companies · $831 in 2025
The $831 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $160 · 2023: $441 · 2024: $514 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $561.07 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $448.23 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $447.72 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $203.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $193.17 | 2021-2024 | |
| Shield Therapeutics INC | $58.59 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $43.58 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $36.76 | 2025 | The Cologuard Plus Collection Kit |
| Currax Pharmaceuticals LLC | $31.67 | 2024-2025 | Contrave, Onzetra Xsail |
| Takeda Pharmaceuticals U.S.A., INC. | $31.27 | 2021-2024 | Trintellix |
| Eisai INC. | $30.70 | 2021 | |
| Pfizer INC. | $24.42 | 2021 | |
| Dexcom, INC. | $22.36 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $19.15 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.08 | 2025 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.64 | 2023 | Rexulti |
| Mylan Specialty L.P. | $13.34 | 2021 | |
| Glaxosmithkline, LLC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.